MDxHealth SA (MDXH) is a multinational healthcare company known for its specialization in the development and marketing of advanced molecular diagnostic products and services. Founded in 2003 and headquartered in Herstal, Belgium, MDxHealth is a pace setter in the field of epigenetics and molecular diagnostics, targeting various cancer types like prostate, bladder, and brain cancer.
MDxHealth SA aims primarily to provide doctors, clinicians and their patients with actionable information that enhances the care and treatment of urological cancer through its testing methodologies. The company boasts a suite of innovative products ranging from ConfirmMDx, which aids in the detection of prostate cancer, to SelectMDx that helps determine the aggressiveness of the disease and necessity of a biopsy.
A key element of MDxHealth's success story lies in its commitment to research and development, underlined by extensive partnerships with academic, clinical and pharmaceutical entities. The company's testing methods rely predominantly on DNA Methylation, considered a significant facet of epigenetics. This process enables MDxHealth to detect genetic changes that can signal potential cancers at an early stage, providing the opportunity for earlier treatment with potentially better outcomes.
MDxHealth has assembled an impressive network, expanding its diagnostics presence across Europe and the United States. The company operates various state-of-the-art laboratories, such as those in Nijmegen, Netherlands, and Irvine, California. These facilities support the global reach and accessibility of MDxHealth's cutting-edge molecular diagnostic products.
The company made a significant impact on healthcare through its commitment to personalized medicine, fostering improved patient outcomes through early intervention and diagnosis. Not only does the company develop and deliver life-changing diagnostic products and services, but it also aids in reducing unnecessary invasive procedures, decreasing patient anxiety and ensuring more effective resource allocation in healthcare delivery.
MDxHealth’s clinical prowess, innovative solutions and strong collaborations have firmly established it as a global leader in the field of molecular diagnostics. Its products and services have revolutionized the approach to diagnosing and treating urological cancers, changing the healthcare landscape while providing hope and reassurance for patients worldwide.
With a reputation for breaking boundaries in patient testing and cancer detection, MDxHealth SA continues to contribute significantly to progressive changes in global healthcare. The company remains committed to its mission – helping physicians diagnose cancer earlier and more accurately thus enhancing the life chances of patients.